In the MDX010-20 study, previously treated patients with unresectable stage III or IV melanoma were randomized to receive ipilimumab alone (n = 136), ipilimumab plus the experimental vaccine glycoprotein 100 (gp100; n = 403), or gp100 alone (n = 136). The gene discussed is PMEL; the disease is melanoma.